Abstract | OBJECTIVE: RESEARCH METHODS AND PROCEDURES: Study 1 compared PPA 12.5 mg tid with 25 mg tid and placebo in a 6-week trial in 108 obese subjects. Study 2 compared pseudoephedrine 120 mg/day and a placebo in a 12-week trial with 72 obese subjects. Study 3 compared 4 groups of 20 obese subjects using PPA 75 mg/day, benzocaine gum 96 mg/day, PPA with benzocaine gum, and a placebo over 12 weeks. RESULTS: Both doses of PPA gave twice the weight loss of placebo, but the difference did not reach statistical significance. Pseudoephedrine was no different than placebo in inducing weight loss. The PPA with benzocaine group had more adverse events than the benzocaine group (p = 0.03), the placebo group (p = 0.03), or the PPA group (p = 0.09) without additional weight loss. DISCUSSION:
|
Authors | F Greenway, D Herber, W Raum, D Herber, S Morales |
Journal | Obesity research
(Obes Res)
Vol. 7
Issue 4
Pg. 370-8
(Jul 1999)
ISSN: 1071-7323 [Print] United States |
PMID | 10440593
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Appetite Depressants
- Delayed-Action Preparations
- Nonprescription Drugs
- Phenylpropanolamine
- Ephedrine
- Benzocaine
|
Topics |
- Adolescent
- Adult
- Aged
- Appetite Depressants
(administration & dosage, therapeutic use)
- Benzocaine
(administration & dosage, therapeutic use)
- Delayed-Action Preparations
(administration & dosage, therapeutic use)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Therapy, Combination
- Ephedrine
(administration & dosage, therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Nonprescription Drugs
(administration & dosage, therapeutic use)
- Obesity
(drug therapy)
- Phenylpropanolamine
(administration & dosage, therapeutic use)
- Weight Loss
|